

ZIOPHARM ONCOLOGY INC  
Form 8-K  
March 26, 2013

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**

Washington, D.C. 20549

**FORM 8-K**

**CURRENT REPORT**

**PURSUANT TO SECTION 13 OR 15(d) OF THE**

**SECURITIES EXCHANGE ACT OF 1934**

**Date of report (Date of earliest event reported): March 26, 2013**

**ZIOPHARM Oncology, Inc.**

(Exact Name of Registrant as Specified in Charter)

**Delaware**  
(State or Other Jurisdiction

of Incorporation)

**001-33038**  
(Commission

File Number)

**84-1475672**  
(IRS Employer

Identification No.)

Edgar Filing: ZIOPHARM ONCOLOGY INC - Form 8-K

**1180 Avenue of the Americas**

**20<sup>th</sup> Floor**

**New York, NY**  
**(Address of Principal Executive Offices)**

**(646) 214-0700**

**10036**  
**(Zip Code)**

**(Registrant's telephone number, including area code)**

**Not applicable**

**(Former Name or Former Address, if Changed Since Last Report)**

Check the appropriate box below if the Form 8-K is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- .. Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425).
- .. Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12).
- .. Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)).
- .. Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)).

**Item 8.01 Other Events**

On March 26, 2013, ZIOPHARM Oncology, Inc., or the Company, issued a press release announcing that its Phase 3 trial of palifosfamide (ZIO-201) in first-line metastatic soft tissue sarcoma, entitled PICASSO 3, did not meet its primary endpoint of progression-free survival. With this outcome, the Company has made the decision to immediately terminate development of palifosfamide in first-line metastatic soft tissue sarcoma and place exclusive strategic focus on its synthetic biology programs, which are being developed in partnership with Intrexon Corporation. A copy of the above referenced press release is filed as Exhibit 99.1 to this Current Report on Form 8-K.

At 8:30 a.m. Eastern Time on March 26, 2013, the Company will hold a conference call to discuss the PICASSO 3 trial.

**Item 9.01 Financial Statements and Exhibits**

(d) Exhibits

**Exhibit**

<b>No.</b>	<b>Description</b>
99.1	Press release of the Company dated March 26, 2013

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ZIOPHARM Oncology, Inc.

Date: March 26, 2013

By: /s/ Caesar J. Belbel

Name: Caesar J. Belbel

Title: Executive Vice President and Chief Legal Officer

**INDEX OF EXHIBITS**

**Exhibit**

<b>No.</b>	<b>Description</b>
99.1	Press release of the Company dated March 26, 2013